• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

For many suffering from depression, traditional therapy and medication are ineffective. A customized treatment may be the answer.

Cue is an intervention platform that converts sensor data collected from smartphones into customized micro-interventions to improve mental health. We looked at the best-fitting personal ML models to each subject using Shapley values to determine their features and predictors. The results revealed distinct characteristics that changed mood in a predictable manner over time.

Predictors of Mood

Depression is a leading cause of mental illness around the world.1 Yet only half of those suffering from the condition receive treatment. In order to improve outcomes, healthcare professionals must be able to recognize and treat patients who have the highest likelihood of responding to certain treatments.

A customized depression treatment is one method of doing this. Using sensors for mobile phones as well as an artificial intelligence voice assistant and other digital tools, researchers at the University of Illinois Chicago (UIC) are working on new ways to determine which patients will benefit from the treatments they receive. Two grants totaling more than $10 million will be used to determine the biological and behavioral factors that predict response.

The majority of research on predictors ketamine for treatment resistant depression depression treatment effectiveness has been focused on sociodemographic and clinical characteristics. These include demographic variables such as age, sex and education, clinical characteristics such as the severity of symptoms and comorbidities and biological markers such as neuroimaging and genetic variation.

While many of these aspects can be predicted from data in medical records, few studies have utilized longitudinal data to study the causes of mood among individuals. Many studies do not take into account the fact that moods can differ significantly between individuals. Therefore, it is important to develop methods that permit the determination and quantification of the individual differences between mood predictors, treatment effects, etc.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This enables the team to create algorithms that can identify different patterns of behavior and emotion that are different between people.

In addition to these methods, the team developed a machine-learning algorithm that models the dynamic variables that influence each person's mood. The algorithm integrates the individual characteristics to create an individual "digital genotype" for each participant.

This digital phenotype was linked to CAT DI scores that are a psychometrically validated symptoms severity scale. However, the correlation was weak (Pearson's r = 0.08, the BH-adjusted p-value was 3.55 x 10-03) and varied widely among individuals.

Predictors of symptoms

Depression is one of the most prevalent causes of disability1, but it is often untreated and not diagnosed. In addition the absence of effective interventions and stigma associated with depressive disorders prevent many individuals from seeking help.

To allow for individualized treatment to improve treatment, identifying the predictors of symptoms is important. The current methods for predicting symptoms rely heavily on clinical interviews, which are not reliable and only identify a handful of symptoms associated with depression.

Machine learning can increase the accuracy of the diagnosis and treatment of depression by combining continuous digital behavior phenotypes collected from smartphone sensors along with a verified mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). Digital phenotypes can be used to capture a large number of unique actions and behaviors that are difficult to capture through interviews, and also allow for continuous, high-resolution measurements.

The study included University of California Los Angeles students with moderate to severe depression treatment depression symptoms who were participating in the Screening and Treatment for Anxiety and Depression program29, which was developed as part of the UCLA Depression Grand Challenge. Participants were directed to online support or in-person clinical treatment according to the severity of their depression. Patients with a CAT DI score of 35 or 65 were assigned to online support via an online peer coach, whereas those who scored 75 were sent to in-person clinical care for psychotherapy.

At the beginning of the interview, participants were asked an array of questions regarding their personal characteristics and psychosocial traits. These included sex, age, education, work, and financial situation; whether they were divorced, married or single; their current suicidal ideas, intent or attempts; as well as the frequency at that they consumed alcohol. Participants also scored their level of depression severity on a 0-100 scale using the CAT-DI. CAT-DI assessments were conducted each other week for the participants that received online support, and once a week for those receiving in-person treatment.

Predictors of Treatment Response

A customized treatment for depression is currently a top research topic and many studies aim to identify predictors that allow clinicians to identify the most effective medications for each individual. Pharmacogenetics, for instance, uncovers genetic variations that affect how the human body metabolizes drugs. This allows doctors to select drugs that are likely to work best for each patient, minimizing the time and effort involved in trials and errors, while avoiding side effects that might otherwise slow the progress of the patient.

Another approach that is promising is to build models for prediction using multiple data sources, combining data from clinical studies and neural imaging data. These models can be used to determine which variables are the most predictive of a specific outcome, such as whether a medication will help with symptoms or mood. These models can be used to determine the patient's response to treatment that is already in place and help doctors maximize the effectiveness of the current treatment.

A new era of research uses machine learning methods such as supervised learning and classification algorithms (like regularized logistic regression or tree-based techniques) to combine the effects of many variables to improve predictive accuracy. These models have been shown to be effective in predicting outcomes of treatment, such as response to antidepressants. These approaches are gaining popularity in psychiatry, and it is likely that they will become the standard for the future of clinical practice.

Research into mild depression treatments's underlying mechanisms continues, as do predictive models based on ML. Recent research suggests that the disorder is associated with dysfunctions in specific neural circuits. This suggests that individualized depression treatment will be built around targeted therapies that target these neural circuits to restore normal function.

One method to achieve this is by using internet-based programs that can provide a more personalized and customized experience for patients. One study found that an internet-based program improved symptoms and improved quality of life for MDD patients. A randomized controlled study of an individualized treatment for depression revealed that a significant number of patients saw improvement over time as well as fewer side effects.

Predictors of adverse effects

In the treatment of depression treatment facility, one of the most difficult aspects is predicting and determining which antidepressant medications will have minimal or zero adverse effects. Many patients are prescribed various drugs before they find a drug that is both effective and well-tolerated. Pharmacogenetics provides a novel and exciting method to choose antidepressant medicines that are more effective and specific.

There are several variables that can be used to determine the antidepressant that should be prescribed, including genetic variations, phenotypes of patients such as ethnicity or gender, and the presence of comorbidities. To identify the most reliable and accurate predictors for a specific treatment, controlled trials that are randomized with larger numbers of participants will be required. This is because the detection of moderators or interaction effects may be much more difficult in trials that focus on a single instance of treatment per participant instead of multiple episodes of treatment over time.

In addition to that, predicting a patient's reaction will likely require information about the severity of symptoms, comorbidities and the patient's subjective perception of effectiveness and tolerability. Currently, only a few easily assessable sociodemographic variables and clinical variables appear to be reliable in predicting the response to MDD. These include gender, age, race/ethnicity, SES, BMI and the presence of alexithymia.

Many challenges remain in the application of pharmacogenetics for extreme depression treatment treatment. First is a thorough understanding of the genetic mechanisms is required as well as an understanding of what is a reliable indicator of treatment response. Ethics like privacy, and the ethical use of genetic information are also important to consider. In the long-term, pharmacogenetics may be a way to lessen the stigma that surrounds mental health treatment and to improve the treatment outcomes for patients with depression. As with any psychiatric approach it is crucial to give careful consideration and implement the plan. The best course of action is to provide patients with an array of effective depression medications and encourage them to talk freely with their doctors about their concerns and experiences.